Published in Vaccine Weekly, May 18th, 2005
According to a study from the United States, "Macromolecules that bind beta-amyloid peptide (A-beta) and neutralize A-beta cytotoxicity offer a promising new approach for treating Alzheimer disease. When the plasma protein, alpha 2-macroglobulin (alpha 2M), is treated with methylamine (alpha 2M-MA), it undergoes conformational change and acquires A-beta-binding activity. In this study, we demonstrate that a chemically stabilized preparation of human alpha 2M conformational intermediates (alpha 2M-cis-Pt/MA) binds A-beta with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.